| (Values in U.S. Thousands) | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 | Dec, 2018 |
| Sales | 12,440 | 72,090 | 13,400 | 3,340 | 12,930 |
| Sales Growth | -82.74% | +437.99% | +301.20% | -74.17% | unch |
| Net Income | -740,870 | -581,780 | -357,940 | -213,260 | -98,420 |
| Net Income Growth | -27.35% | -62.54% | -67.84% | -116.68% | -39.74% |
Mirati Therapeutics (MRTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Mirati Therapeutics, Inc. is a clinical-stage biotech developing kinase inhibitors and KRAS inhibitors.
Fiscal Year End Date: 12/31